More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$33.92B
EPS
5.88
P/E ratio
12.3
Price to sales
3.25
Dividend yield
2.54%
Beta
0.673243
Previous close
$84.39
Today's open
$84.05
Day's range
$83.05 - $85.56
52 week range
$68.77 - $132.49
show more
CEO
Kristin C. Peck
Employees
14500
Headquarters
Parsippany, NJ
Exchange
New York Stock Exchange
Shares outstanding
406316147
Issue type
Common Stock
Healthcare
Pharmaceuticals
Zoetis Inc. (ZTS) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Zoetis Inc. (ZTS) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • Nov 16, 2026

Top 50 High-Quality Dividend Growth Stocks For November 2026
I track 50 high-quality dividend growth stocks to identify favorable entry points, prioritizing long-term total return alongside a growing dividend stream. Forty stocks offer estimated future returns of at least 10%; 27 appear undervalued relative to historical free cash flow. ResMed leads with 41.60% estimated return potential; MarketAxess rose to fifth at 28.50% after a valuation upgrade and higher fair value estimate.
Seeking Alpha • Nov 14, 2026

Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief
ZTS' Cytopoint Plus secures a USDA license, offering dogs with allergic dermatitis 75 days of itch relief and a longer interval between injections.
Zacks Investment Research • Nov 12, 2026

SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For November 2026
The 4-Factor Dividend Growth Strategy targets quality and total return, outperforming SCHD with a 14.98% average return versus SCHD's 14.31%. I select stocks based on free cash flow to debt, 5-year dividend growth, return on capital employed, and forward yield, emphasizing growth and quality. Recent SCHD outperformance has narrowed the gap, but my strategy has regained momentum since September 2026.
Seeking Alpha • Nov 12, 2026

Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Cytopoint Plus is the first and only USDA-licensed next-generation mAb that provides 75 days of allergic itch relief in a single injection.
Business Wire • Nov 11, 2026

Zoetis to Participate in the Jefferies Global Healthcare Conference in London
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 2 p.m. GMT. Interested parties can access the live webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event.
Business Wire • Nov 10, 2026

ZTS Q3 Earnings Call Highlights Competitive Pressures and Outlook
Zoetis beats Q3 earnings estimates despite revenue weakness, as competitive pressures, targeted promotions and product innovation shape its cautious 2027 outlook.
Zacks Investment Research • Nov 9, 2026

What Zoetis (ZTS) Said on Its Q3 Earnings Call
Zoetis NYSE: ZTS reported lower third-quarter revenue as competition and weaker veterinary visits pressured its companion animal business, while livestock and diagnostics provided growth. The animal health company narrowed its full-year revenue outlook to the high end of its previous range and raised its adjusted earnings guidance.
MarketBeat • Nov 8, 2026

Zoetis Inc. (ZTS) Q3 2026 Earnings Call Transcript
Zoetis Inc. ( ZTS ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Mathieu Aussermeier Kristin Peck - CEO & Director James Saccaro - Executive VP, CFO & COO Conference Call Participants Christopher Schott - JPMorgan Chase & Co, Research Division David Westenberg - Piper Sandler & Co., Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Brandon Vazquez - William Blair & Company L.L.C., Research Division Erin Wilson Wright - Morgan Stanley, Research Division Matthew Dellatorre - Goldman Sachs Group, Inc., Research Division Navann Ty Dietschi - BNP Paribas, Research Division Christopher LoBianco - TD Cowen, Research Division Andrea Zayco Narvaez Alfonso - UBS Investment Bank, Research Division Steven Dechert - KeyBanc Capital Markets Inc., Research Division Presentation Operator Welcome to the third quarter 2026 financial results conference call and webcast for Zoetis.
Seeking Alpha • Nov 6, 2026

Zoetis: Quality Company Trading Cheap
Zoetis Inc., formerly Pfizer's veterinary arm, is a global leader in animal pharmaceuticals and diagnostics. ZTS generates most revenue from companion animal products, with approximately 30% from livestock healthcare solutions. We review why the stock has done so poorly and tell you why we went long.
Seeking Alpha • Nov 6, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Zoetis Inc. Class A commission-free¹. Build wealth for the long term using automated trading and transfers.